speb/financial-data huggingface dataset:
DBD balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 2003400000.00
DBD balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 1361200000.00
DBD income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 56200000.00
DBD income_statement (quarterly, 2025-06-30) — Total Unusual Items: -28500000.00
DBD income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -28500000.00
DBD balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 855443.00
DBD balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 39700000.00
DBD balance_sheet (quarterly, 2025-06-30) — Working Capital: 462800000.00
DBD income_statement (quarterly, 2025-09-30) — +Operating Expense: 171300000.00
DBD income_statement (quarterly, 2025-09-30) — +Total Revenue: 945200000.00
DBD balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 461700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 580100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -68900000.00
DBD balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1057700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -10600000.00
DBD cash_flow (quarterly, 2025-09-30) — Amortization Cash Flow: 23100000.00
DBD cash_flow (quarterly, 2025-09-30) — Amortization Of Intangibles: 23100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Assets Held For Sale Current: 5500000.00
DBD income_statement (quarterly, 2025-09-30) — Basic Average Shares: 36500000.00
DBD income_statement (quarterly, 2025-09-30) — Basic EPS: 1.13
DBD cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 295200000.00
DBD cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -12900000.00
DBD cash_flow (quarterly, 2025-09-30) — Capital Expenditure Reported: -12900000.00
DBD balance_sheet (quarterly, 2025-09-30) — Capital Stock: 400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 246100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 263500000.00
DBD cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -44100000.00
DBD cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -26200000.00
DBD cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 37400000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 29700000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: -500000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Inventory: -18200000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -50800000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Payable: 29700000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 29200000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Receivables: 20600000.00
DBD cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -19200000.00
DBD cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 20600000.00
DBD cash_flow (quarterly, 2025-09-30) — Changes In Cash: -32900000.00
DBD balance_sheet (quarterly, 2025-09-30) — Common Stock: 400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 1107200000.00
DBD cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -39900000.00
DBD income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 700100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 168700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Current Assets: 1721700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 300600000.00
DBD balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 300600000.00
DBD balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1263400000.00
DBD cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -22700000.00
DBD cash_flow (quarterly, 2025-09-30) — Deferred Tax: -22700000.00
DBD cash_flow (quarterly, 2025-09-30) — Depreciation: 8500000.00
DBD cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 31700000.00
DBD cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 31700000.00
DBD income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 37000000.00
DBD income_statement (quarterly, 2025-09-30) — Diluted EPS: 1.11
DBD income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 41100000.00
DBD income_statement (quarterly, 2025-09-30) — EBIT: 74200000.00
DBD income_statement (quarterly, 2025-09-30) — EBITDA: 105900000.00
DBD income_statement (quarterly, 2025-09-30) — Earnings From Equity Interest Net Of Tax: -1100000.00
DBD cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 300000.00
DBD balance_sheet (quarterly, 2025-09-30) — Employee Benefits: 127900000.00
DBD cash_flow (quarterly, 2025-09-30) — End Cash Position: 262600000.00
DBD cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -44100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Finished Goods: 231500000.00
DBD cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 24500000.00
DBD income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -800000.00
DBD balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 84800000.00
DBD balance_sheet (quarterly, 2025-09-30) — Goodwill: 642100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 1450200000.00
DBD balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 590700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Gross PPE: 336400000.00
DBD income_statement (quarterly, 2025-09-30) — Gross Profit: 245100000.00
DBD cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 8500000.00
DBD income_statement (quarterly, 2025-09-30) — Interest Expense: 21800000.00
DBD income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 21800000.00
DBD income_statement (quarterly, 2025-09-30) — Interest Income: 2100000.00
DBD income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 2100000.00
DBD cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 37100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Inventory: 599700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Invested Capital: 2041200000.00
DBD cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -26200000.00
DBD cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 0.00
DBD balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 934000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 934000000.00
DBD cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: 0.00
DBD cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
DBD balance_sheet (quarterly, 2025-09-30) — Minority Interest: 5200000.00
DBD income_statement (quarterly, 2025-09-30) — Minority Interests: -600000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -39900000.00
DBD balance_sheet (quarterly, 2025-09-30) — Net Debt: 687900000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: 1000000.00
DBD income_statement (quarterly, 2025-09-30) — Net Income: 41100000.00
DBD income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 41100000.00
DBD income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 41700000.00
DBD income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 41100000.00
DBD income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 41100000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 41700000.00
DBD income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 41700000.00
DBD income_statement (quarterly, 2025-09-30) — Net Interest Income: -19700000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 7600000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: 0.00
DBD cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 0.00
DBD income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -19700000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -4200000.00
DBD cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -2500000.00
DBD balance_sheet (quarterly, 2025-09-30) — Net PPE: 267500000.00
DBD balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -343000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 71000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 161300000.00
DBD balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 71000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 161300000.00
DBD balance_sheet (quarterly, 2025-09-30) — Non Current Pension And Other Postretirement Benefit Plans: 127900000.00
DBD income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 106700000.00
DBD income_statement (quarterly, 2025-09-30) — Normalized Income: 41753600.00
DBD cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 37400000.00
DBD cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 1000000.00
DBD income_statement (quarterly, 2025-09-30) — Operating Income: 73800000.00
DBD income_statement (quarterly, 2025-09-30) — Operating Revenue: 945200000.00
DBD balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 36202209.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 216000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 332400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 84800000.00
DBD income_statement (quarterly, 2025-09-30) — Other Income Expense: -1700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 808100000.00
DBD cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 1900000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 213400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 124800000.00
DBD income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -900000.00
DBD income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Properties: 336400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 17400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Payables: 461700000.00
DBD balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 630400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 40400000.00
DBD income_statement (quarterly, 2025-09-30) — Pretax Income: 52400000.00
DBD cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -71000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Raw Materials: 368200000.00
DBD balance_sheet (quarterly, 2025-09-30) — Receivables: 580100000.00
DBD income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 700100000.00
DBD income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 31700000.00
DBD cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: 0.00
DBD cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -39900000.00
DBD income_statement (quarterly, 2025-09-30) — Research And Development: 20300000.00
DBD balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 16500000.00
DBD balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 43900000.00
DBD cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 78600000.00
DBD income_statement (quarterly, 2025-09-30) — Selling General And Administration: 150900000.00
DBD balance_sheet (quarterly, 2025-09-30) — Share Issued: 37725053.00
DBD cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 3000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 1107200000.00
DBD balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -343000000.00
DBD income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -146400.00
DBD income_statement (quarterly, 2025-09-30) — Tax Provision: 9600000.00
DBD income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.18
DBD balance_sheet (quarterly, 2025-09-30) — Total Assets: 3723800000.00
DBD balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 2041200000.00
DBD balance_sheet (quarterly, 2025-09-30) — Total Debt: 934000000.00
DBD balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 1112400000.00
DBD income_statement (quarterly, 2025-09-30) — Total Expenses: 871400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2611400000.00
DBD balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 2002100000.00
DBD balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 1348000000.00
DBD income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 73800000.00
DBD income_statement (quarterly, 2025-09-30) — Total Unusual Items: -800000.00
DBD income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -800000.00
DBD balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 1522844.00
DBD balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 79600000.00
DBD balance_sheet (quarterly, 2025-09-30) — Working Capital: 458300000.00
DBD income_statement (annual, 2025-12-31) — +Operating Expense: 719200000.00
DBD income_statement (quarterly, 2025-12-31) — +Operating Expense: 197400000.00
DBD income_statement (annual, 2025-12-31) — +Total Revenue: 3805700000.00
DBD income_statement (quarterly, 2025-12-31) — +Total Revenue: 1104200000.00
DBD balance_sheet (annual, 2025-12-31) — Accounts Payable: 431100000.00
DBD balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 431100000.00
DBD balance_sheet (annual, 2025-12-31) — Accounts Receivable: 609400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 609400000.00
DBD balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -81000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -81000000.00
DBD balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1060500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1060500000.00
DBD balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -6000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -6000000.00
DBD income_statement (annual, 2025-12-31) — Basic Average Shares: 36800000.00
DBD income_statement (quarterly, 2025-12-31) — Basic Average Shares: 35800000.00
DBD income_statement (annual, 2025-12-31) — Basic EPS: 2.57
DBD income_statement (quarterly, 2025-12-31) — Basic EPS: 1.39
DBD cash_flow (annual, 2025-12-31) — Beginning Cash Position: 311300000.00
DBD cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 262600000.00
DBD balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 52400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 52400000.00
DBD cash_flow (annual, 2025-12-31) — Capital Expenditure: -61700000.00
DBD cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -21800000.00
DBD cash_flow (annual, 2025-12-31) — Capital Expenditure Reported: -61700000.00
DBD cash_flow (quarterly, 2025-12-31) — Capital Expenditure Reported: -21800000.00
DBD balance_sheet (annual, 2025-12-31) — Capital Stock: 400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Capital Stock: 400000.00
DBD balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 368900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 368900000.00
DBD balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 398000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 398000000.00
DBD cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -143900000.00
DBD cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -55700000.00
DBD cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -97600000.00
DBD cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -38600000.00
DBD cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 300700000.00
DBD cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 217500000.00
DBD cash_flow (annual, 2025-12-31) — Change In Account Payable: -68300000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -31300000.00
DBD cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 34100000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 51400000.00
DBD cash_flow (annual, 2025-12-31) — Change In Inventory: 65100000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Inventory: 78300000.00
DBD cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 9000000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: 81300000.00
DBD cash_flow (annual, 2025-12-31) — Change In Payable: -68300000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Payable: -31300000.00
DBD cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -34200000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 20100000.00
DBD cash_flow (annual, 2025-12-31) — Change In Receivables: 25900000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Receivables: -28100000.00
DBD cash_flow (annual, 2025-12-31) — Change In Working Capital: 65800000.00
DBD cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 151600000.00
DBD cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 25900000.00
DBD cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -28100000.00
DBD cash_flow (annual, 2025-12-31) — Changes In Cash: 59200000.00
DBD cash_flow (quarterly, 2025-12-31) — Changes In Cash: 123200000.00
DBD balance_sheet (annual, 2025-12-31) — Common Stock: 400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Common Stock: 400000.00
DBD balance_sheet (annual, 2025-12-31) — Common Stock Equity: 1099900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 1099900000.00
DBD cash_flow (annual, 2025-12-31) — Common Stock Payments: -130700000.00
DBD cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -51100000.00
DBD balance_sheet (annual, 2025-12-31) — Construction In Progress: 19700000.00
DBD balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 19700000.00
DBD income_statement (annual, 2025-12-31) — Cost Of Revenue: 2844500000.00
DBD income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 824400000.00
DBD balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 201600000.00
DBD balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 201600000.00
DBD balance_sheet (annual, 2025-12-31) — Current Assets: 1786800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Current Assets: 1786800000.00
DBD balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 325800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 325800000.00
DBD balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 325800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 325800000.00
DBD balance_sheet (annual, 2025-12-31) — Current Liabilities: 1371500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 1371500000.00
DBD cash_flow (annual, 2025-12-31) — Deferred Income Tax: -48100000.00
DBD cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -16600000.00
DBD cash_flow (annual, 2025-12-31) — Deferred Tax: -48100000.00
DBD cash_flow (quarterly, 2025-12-31) — Deferred Tax: -16600000.00
DBD cash_flow (annual, 2025-12-31) — Depreciation: 127500000.00
DBD cash_flow (quarterly, 2025-12-31) — Depreciation: 101400000.00
DBD cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 127500000.00
DBD cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 30700000.00
DBD cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 127500000.00
DBD cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 30700000.00
DBD income_statement (annual, 2025-12-31) — Diluted Average Shares: 37200000.00
DBD income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 36300000.00
DBD income_statement (annual, 2025-12-31) — Diluted EPS: 2.54
DBD income_statement (quarterly, 2025-12-31) — Diluted EPS: 1.37
DBD income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 94600000.00
DBD income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 49600000.00
DBD income_statement (annual, 2025-12-31) — EBIT: 210800000.00
DBD income_statement (quarterly, 2025-12-31) — EBIT: 83400000.00
DBD income_statement (annual, 2025-12-31) — EBITDA: 338300000.00
DBD income_statement (quarterly, 2025-12-31) — EBITDA: 114100000.00
DBD income_statement (annual, 2025-12-31) — Earnings From Equity Interest Net Of Tax: -3500000.00
DBD income_statement (quarterly, 2025-12-31) — Earnings From Equity Interest Net Of Tax: -400000.00
DBD cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 16800000.00
DBD cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 1500000.00
DBD balance_sheet (annual, 2025-12-31) — Employee Benefits: 120400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Employee Benefits: 120400000.00
DBD cash_flow (annual, 2025-12-31) — End Cash Position: 387300000.00
DBD cash_flow (quarterly, 2025-12-31) — End Cash Position: 387300000.00
DBD cash_flow (annual, 2025-12-31) — Financing Cash Flow: -143900000.00
DBD cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -55700000.00
DBD balance_sheet (annual, 2025-12-31) — Finished Goods: 154000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Finished Goods: 154000000.00
DBD cash_flow (annual, 2025-12-31) — Free Cash Flow: 239000000.00
DBD cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 195700000.00
DBD income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -44100000.00
DBD income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -2600000.00
DBD balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 77800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 77800000.00
DBD balance_sheet (annual, 2025-12-31) — Goodwill: 642400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Goodwill: 642400000.00
DBD balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 1434800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 1434800000.00
DBD balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 615400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 615400000.00
DBD balance_sheet (annual, 2025-12-31) — Gross PPE: 367000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Gross PPE: 367000000.00
DBD income_statement (annual, 2025-12-31) — Gross Profit: 961200000.00
DBD income_statement (quarterly, 2025-12-31) — Gross Profit: 279800000.00
DBD cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 57200000.00
DBD cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 21300000.00
DBD income_statement (annual, 2025-12-31) — Interest Expense: 85700000.00
DBD income_statement (quarterly, 2025-12-31) — Interest Expense: 20600000.00
DBD income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 85700000.00
DBD income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 20600000.00
DBD income_statement (annual, 2025-12-31) — Interest Income: 8900000.00
DBD income_statement (quarterly, 2025-12-31) — Interest Income: 2800000.00
DBD income_statement (annual, 2025-12-31) — Interest Income Non Operating: 8900000.00
DBD income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 2800000.00
DBD cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 59100000.00
DBD cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 300000.00
DBD balance_sheet (annual, 2025-12-31) — Inventory: 521000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Inventory: 521000000.00
DBD balance_sheet (annual, 2025-12-31) — Invested Capital: 2038400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Invested Capital: 2038400000.00
DBD cash_flow (annual, 2025-12-31) — Investing Cash Flow: -97600000.00
DBD cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -38600000.00
DBD cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
DBD cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 0.00
DBD balance_sheet (annual, 2025-12-31) — Land And Improvements: 19300000.00
DBD balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 19300000.00
DBD balance_sheet (annual, 2025-12-31) — Leases: 10500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Leases: 10500000.00
DBD balance_sheet (annual, 2025-12-31) — Long Term Debt: 938500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 938500000.00
DBD balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 938500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 938500000.00
DBD cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 0.00
DBD cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
DBD cash_flow (annual, 2025-12-31) — Long Term Debt Payments: 0.00
DBD cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 0.00
DBD balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 96900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 96900000.00
DBD balance_sheet (annual, 2025-12-31) — Minority Interest: 4900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Minority Interest: 4900000.00
DBD income_statement (annual, 2025-12-31) — Minority Interests: -2900000.00
DBD income_statement (quarterly, 2025-12-31) — Minority Interests: -900000.00
DBD cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -24500000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -6100000.00
DBD cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -130700000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -51100000.00
DBD balance_sheet (annual, 2025-12-31) — Net Debt: 569600000.00
DBD balance_sheet (quarterly, 2025-12-31) — Net Debt: 569600000.00
DBD cash_flow (annual, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: 38800000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: -3500000.00
DBD income_statement (annual, 2025-12-31) — Net Income: 94600000.00
DBD income_statement (quarterly, 2025-12-31) — Net Income: 49600000.00
DBD income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 94600000.00
DBD income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 49600000.00
DBD income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 97500000.00
DBD income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 50500000.00
DBD income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 94600000.00
DBD income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 49600000.00
DBD income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 94600000.00
DBD income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 49600000.00
DBD cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 97500000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 50500000.00
DBD income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 97500000.00
DBD income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 50500000.00
DBD income_statement (annual, 2025-12-31) — Net Interest Income: -76800000.00
DBD income_statement (quarterly, 2025-12-31) — Net Interest Income: -17800000.00
DBD cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -12400000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -12400000.00
DBD cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 0.00
DBD cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 0.00
DBD cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 0.00
DBD cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 0.00
DBD income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -76800000.00
DBD income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -17800000.00
DBD cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -13200000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -4600000.00
DBD cash_flow (annual, 2025-12-31) — Net Other Investing Changes: 1000000.00
DBD cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: 1700000.00
DBD balance_sheet (annual, 2025-12-31) — Net PPE: 286000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Net PPE: 286000000.00
DBD balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -334900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -334900000.00
DBD balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 105000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 105000000.00
DBD balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 200700000.00
DBD balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 200700000.00
DBD balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 105000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 105000000.00
DBD balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 200700000.00
DBD balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 200700000.00
DBD balance_sheet (annual, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 120400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 120400000.00
DBD income_statement (annual, 2025-12-31) — Normalized EBITDA: 382400000.00
DBD income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 116700000.00
DBD income_statement (annual, 2025-12-31) — Normalized Income: 130188700.00
DBD income_statement (quarterly, 2025-12-31) — Normalized Income: 51707324.84
DBD cash_flow (annual, 2025-12-31) — Operating Cash Flow: 300700000.00
DBD cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 217500000.00
DBD cash_flow (annual, 2025-12-31) — Operating Gains Losses: 38800000.00
DBD cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -3500000.00
DBD income_statement (annual, 2025-12-31) — Operating Income: 242000000.00
DBD income_statement (quarterly, 2025-12-31) — Operating Income: 82400000.00
DBD income_statement (annual, 2025-12-31) — Operating Revenue: 3805700000.00
DBD income_statement (quarterly, 2025-12-31) — Operating Revenue: 1104200000.00
DBD balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 35384690.00
DBD balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 35384690.00
DBD cash_flow (annual, 2025-12-31) — Other Cash Adjustment Outside Changein Cash: 0.00
DBD balance_sheet (annual, 2025-12-31) — Other Current Assets: 189100000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 189100000.00
DBD balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 413000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 413000000.00
DBD balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 77800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 77800000.00
DBD income_statement (annual, 2025-12-31) — Other Income Expense: -40100000.00
DBD income_statement (quarterly, 2025-12-31) — Other Income Expense: -1800000.00
DBD balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 792400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 792400000.00
DBD cash_flow (annual, 2025-12-31) — Other Non Cash Items: 7100000.00
DBD cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 2000000.00
DBD balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 241800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 241800000.00
DBD balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 118500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 118500000.00
DBD income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 4000000.00
DBD income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 800000.00
DBD balance_sheet (annual, 2025-12-31) — Other Properties: 168200000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Properties: 168200000.00
DBD balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 29100000.00
DBD balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 29100000.00
DBD balance_sheet (annual, 2025-12-31) — Payables: 431100000.00
DBD balance_sheet (quarterly, 2025-12-31) — Payables: 431100000.00
DBD balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 632700000.00
DBD balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 632700000.00
DBD balance_sheet (annual, 2025-12-31) — Prepaid Assets: 50900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 50900000.00
DBD income_statement (annual, 2025-12-31) — Pretax Income: 125100000.00
DBD income_statement (quarterly, 2025-12-31) — Pretax Income: 62800000.00
DBD balance_sheet (annual, 2025-12-31) — Properties: 0.00
DBD balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
DBD cash_flow (annual, 2025-12-31) — Purchase Of Business: -24500000.00
DBD cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -6100000.00
DBD cash_flow (annual, 2025-12-31) — Purchase Of Investment: -318400000.00
DBD cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -95300000.00
DBD balance_sheet (annual, 2025-12-31) — Raw Materials: 367000000.00
DBD balance_sheet (quarterly, 2025-12-31) — Raw Materials: 367000000.00
DBD balance_sheet (annual, 2025-12-31) — Receivables: 609400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Receivables: 609400000.00
DBD income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 2844500000.00
DBD income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 824400000.00
DBD income_statement (annual, 2025-12-31) — Reconciled Depreciation: 127500000.00
DBD income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 30700000.00
DBD cash_flow (annual, 2025-12-31) — Repayment Of Debt: 0.00
DBD cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: 0.00
DBD cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -130700000.00
DBD cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -51100000.00
DBD income_statement (annual, 2025-12-31) — Research And Development: 86700000.00
DBD income_statement (quarterly, 2025-12-31) — Research And Development: 21400000.00
DBD balance_sheet (annual, 2025-12-31) — Restricted Cash: 18400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 18400000.00
DBD income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 0.00
DBD balance_sheet (annual, 2025-12-31) — Retained Earnings: 91900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 91900000.00
DBD cash_flow (annual, 2025-12-31) — Sale Of Investment: 306000000.00
DBD cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 82900000.00
DBD income_statement (annual, 2025-12-31) — Selling General And Administration: 632500000.00
DBD income_statement (quarterly, 2025-12-31) — Selling General And Administration: 175600000.00
DBD balance_sheet (annual, 2025-12-31) — Share Issued: 37726003.00
DBD balance_sheet (quarterly, 2025-12-31) — Share Issued: 37726003.00
DBD income_statement (annual, 2025-12-31) — Special Income Charges: 0.00
DBD cash_flow (annual, 2025-12-31) — Stock Based Compensation: 12100000.00
DBD cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 2800000.00
DBD balance_sheet (annual, 2025-12-31) — Stockholders Equity: 1099900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 1099900000.00
DBD balance_sheet (annual, 2025-12-31) — Tangible Book Value: -334900000.00
DBD balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -334900000.00
DBD income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -8511300.00
DBD income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -492675.16
DBD income_statement (annual, 2025-12-31) — Tax Provision: 24100000.00
DBD income_statement (quarterly, 2025-12-31) — Tax Provision: 11900000.00
DBD income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.19
DBD income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.19
DBD balance_sheet (annual, 2025-12-31) — Total Assets: 3854400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Assets: 3854400000.00
DBD balance_sheet (annual, 2025-12-31) — Total Capitalization: 2038400000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 2038400000.00
DBD balance_sheet (annual, 2025-12-31) — Total Debt: 938500000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Debt: 938500000.00
DBD balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 1104800000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 1104800000.00
DBD income_statement (annual, 2025-12-31) — Total Expenses: 3563700000.00
DBD income_statement (quarterly, 2025-12-31) — Total Expenses: 1021800000.00
DBD balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 2749600000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 2749600000.00
DBD balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 2067600000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 2067600000.00
DBD balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1378100000.00
DBD balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1378100000.00
DBD income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 242000000.00
DBD income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 82400000.00
DBD income_statement (annual, 2025-12-31) — Total Unusual Items: -44100000.00
DBD income_statement (quarterly, 2025-12-31) — Total Unusual Items: -2600000.00
DBD income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -44100000.00
DBD income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -2600000.00
DBD balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 2341313.00
DBD balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 2341313.00
DBD balance_sheet (annual, 2025-12-31) — Treasury Stock: 130700000.00
DBD balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 130700000.00
DBD balance_sheet (annual, 2025-12-31) — Working Capital: 415300000.00
DBD balance_sheet (quarterly, 2025-12-31) — Working Capital: 415300000.00
DBD income_statement (annual, 2025-12-31) — Write Off: 0.00
DBD income_statement (quarterly, 2026-03-31) — +Operating Expense: 168500000.00
DBD income_statement (quarterly, 2026-03-31) — +Total Revenue: 891800000.00
DBD balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 482600000.00
DBD balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 597000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -84000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1064000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -4000000.00
DBD cash_flow (quarterly, 2026-03-31) — Amortization Cash Flow: 25000000.00
DBD cash_flow (quarterly, 2026-03-31) — Amortization Of Intangibles: 25000000.00
DBD income_statement (quarterly, 2026-03-31) — Basic Average Shares: 35100000.00
DBD income_statement (quarterly, 2026-03-31) — Basic EPS: 0.14
DBD cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 387300000.00
DBD cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -11000000.00
DBD cash_flow (quarterly, 2026-03-31) — Capital Expenditure Reported: -11000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Capital Stock: 400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 373600000.00
DBD balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 373600000.00
DBD cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -62200000.00
DBD cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 20200000.00
DBD cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 31700000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 59000000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -28700000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Inventory: -38700000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -7600000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Payable: 59000000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 30300000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Receivables: 3800000.00
DBD cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -12200000.00
DBD cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 3800000.00
DBD cash_flow (quarterly, 2026-03-31) — Changes In Cash: -10300000.00
DBD balance_sheet (quarterly, 2026-03-31) — Common Stock: 400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1022900000.00
DBD cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -60400000.00
DBD income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 678700000.00
DBD balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 165600000.00
DBD balance_sheet (quarterly, 2026-03-31) — Current Assets: 1800100000.00
DBD balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 359400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 359400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1404000000.00
DBD cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: 1300000.00
DBD cash_flow (quarterly, 2026-03-31) — Deferred Tax: 1300000.00
DBD cash_flow (quarterly, 2026-03-31) — Depreciation: 6400000.00
DBD cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 31400000.00
DBD cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 31400000.00
DBD income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 35700000.00
DBD income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.14
DBD income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 5000000.00
DBD income_statement (quarterly, 2026-03-31) — EBIT: 35700000.00
DBD income_statement (quarterly, 2026-03-31) — EBITDA: 67100000.00
DBD income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest Net Of Tax: -1200000.00
DBD cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -3400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Employee Benefits: 115900000.00
DBD cash_flow (quarterly, 2026-03-31) — End Cash Position: 373600000.00
DBD cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -62200000.00
DBD balance_sheet (quarterly, 2026-03-31) — Finished Goods: 179000000.00
DBD cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 20700000.00
DBD income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -2400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 52700000.00
DBD balance_sheet (quarterly, 2026-03-31) — Goodwill: 632100000.00
DBD balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1396700000.00
DBD balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 601000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Gross PPE: 377000000.00
DBD income_statement (quarterly, 2026-03-31) — Gross Profit: 213100000.00
DBD cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 6000000.00
DBD income_statement (quarterly, 2026-03-31) — Interest Expense: 23300000.00
DBD income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 23300000.00
DBD income_statement (quarterly, 2026-03-31) — Interest Income: 2900000.00
DBD income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 2900000.00
DBD cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 37100000.00
DBD balance_sheet (quarterly, 2026-03-31) — Inventory: 553100000.00
DBD balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1962300000.00
DBD cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 20200000.00
DBD balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 939400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 939400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Minority Interest: 3300000.00
DBD income_statement (quarterly, 2026-03-31) — Minority Interests: -500000.00
DBD cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -60400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Net Debt: 565800000.00
DBD cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -600000.00
DBD income_statement (quarterly, 2026-03-31) — Net Income: 5000000.00
DBD income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 5000000.00
DBD income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 5500000.00
DBD income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 5000000.00
DBD income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 5000000.00
DBD cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 5500000.00
DBD income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 5500000.00
DBD income_statement (quarterly, 2026-03-31) — Net Interest Income: -20400000.00
DBD cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 29100000.00
DBD income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -20400000.00
DBD cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -1800000.00
DBD cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: 2100000.00
DBD balance_sheet (quarterly, 2026-03-31) — Net PPE: 293000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -373800000.00
DBD balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 103300000.00
DBD balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 197000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 103300000.00
DBD balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 197000000.00
DBD balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 115900000.00
DBD income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 81400000.00
DBD income_statement (quarterly, 2026-03-31) — Normalized Income: 13580000.00
DBD cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 31700000.00
DBD cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -600000.00
DBD income_statement (quarterly, 2026-03-31) — Operating Income: 44600000.00
DBD income_statement (quarterly, 2026-03-31) — Operating Revenue: 891800000.00
DBD balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 34751349.00
DBD balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 245300000.00
DBD balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 396400000.00
DBD balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 52700000.00